摘要
卵巢癌是女性生殖器官中常见的恶性肿瘤之一,是女性生殖系统肿瘤中的最大杀手。随着分子遗传学和肿瘤生物学研究的深入发展,基因诊断已成为治疗恶性肿瘤的重要手段。因此,研究卵巢癌的分子遗传学机制进而了解其生物学效应对卵巢癌的发生发展、治疗及预后等方面有重要意义。大量临床病理学和分子遗传学实验证明ERK1/2通路异常活动与低级浆液性卵巢癌的发生发展关系密切。文章将针对ERK1/2通路的异常持续活化(KRAS或BRAF突变次级效应)与低级浆液性卵巢癌发生发展的关联性研究作一简要综述。
Ovarian cancer is one of the common neoplasms of female reproductive organs. The mortali- ty topped the list of all kinds of reproductive neoplasm. With the development of molecular genetics and cancer genetics,the genetic diagnosis has become the important approach of malignancy cure. Thus, learning the molecular genetics mechanism of ovarian cancer is of great meaning for the disease, including the portent,the treatment and the prognosis of disease. A large number of clinical pathology and molecular genetics experiments proved that there was close correlation between the abnormal ac- tivities of ERK1/2 pathway and the cancer development. This review summarizes the latest study on ERK1/2 pathway,mainly about the KRAS or BRAF mutation,and the development of ERK1/2 pathway in low-grade ovarian serous tumors.
出处
《肿瘤学杂志》
CAS
2013年第8期585-589,共5页
Journal of Chinese Oncology
基金
国家国际科技合作专项项目(2013DFA31610)
教育部创新团队(IRT1230)
国家自然科学基金(31000626
31271347)
教育部新世纪优秀人才计划(NCET-10-0149
NCET-11-0954)
